Drug survival of adalimumab across different manifestations of Behçet’s syndrome: a retrospective analysis in 335 patients

Clicks: 19
ID: 328759
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #146 of 339 articles by views in Lara D. Veeken

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 339 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Objectives Studies on drug survival provide real-world data on efficacy as well as safety. We aimed to evaluate the long-term drug survival of adalimumab (ADA) in a large cohort of patients with Behçet’s syndrome (BS). Methods We conducted a retrospective chart review of 335 BS patients who started ADA between 2008 and 2023. All treatment discontinuations were considered as events, regardless of the underlying reason, to reflect overall treatment persistence in a real-world setting. Results ADA retention rates at 6, 12, and 24 months were 88.9%, 78.3%, and 67.1%, respectively. Over a mean follow-up of 26.6 (23) months, 137 patients (41%) discontinued ADA. The most common reason for discontinuation was inefficacy, followed by adverse events, non-compliance, remission, and other reasons. No significant associations were observed between treatment discontinuation and age, sex, disease duration, prior tumor necrosis factor inhibitor exposure, concomitant disease-modifying antirheumatic drug use, or major organ involvement. Dose interval extension was performed in 36 patients, with relapse or flare occurring in 5 (14%), all of whom achieved remission after dose re-adjustment. Dose intensification was applied in 30 patients, resulting in remission in 17 (56.6%). Conclusion ADA showed a good retention rate at month 6, followed by a gradual decline in drug retention over time. Secondary inefficacy was the most common reason for treatment discontinuation, followed by adverse events and non-compliance, whereas primary inefficacy was uncommon. Dose intensification to achieve active disease control and dose de-escalation in patients with sustained remission may be feasible management strategies.
Reference Key
openalex_W7213451282 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Özge Sönmez, Sinem Nihal Esatoğlu, Didar Uçar, Elif Kaymaz, Yeşim Özgüler, Serdal Ugurlu, Emire Seyahi, Melike Melikoglu, Izzet Fresko, Uğur Uygunoğlu, Muazzez Çiğdem Oba, Zekayi Kutlubay, Ali İbrahim Hatemi, Aykut Ferhat Çelık, Vedat Hamuryudan, Gulen Hatemi
Are you one of these authors? Claim your profile
Journal Lara D. Veeken
Year 2026
DOI
10.1093/rheumatology/keag510
URL
https://doi.org/10.1093/rheumatology/keag510
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.